Ken Griffin Zynerba Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$0.3 - $0.43 $3,690 - $5,289
12,300 Added 93.18%
25,500 $8,000
Q1 2023

May 15, 2023
SELL
$0.4 - $0.67 $3,080 - $5,159
-7,700 Reduced 36.84%
13,200 $5,000
Q4 2022

Feb 14, 2023
SELL
$0.5 - $0.72 $8,100 - $11,664
-16,200 Reduced 43.67%
20,900 $11,000
Q3 2022

Nov 14, 2022
BUY
$0.87 - $1.36 $2,697 - $4,216
3,100 Added 9.12%
37,100 $27,000

Others Institutions Holding ZYNE

# of Institutions
4
Shares Held
774K
Call Options Held
0
Put Options Held
0
View Full List

About Zynerba Pharmaceuticals, Inc.

ZYNE Quotes by TradingView
  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email